Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry

Jennifer A Rymer, Deepak L Bhatt, Dominick J Angiolillo, Miguel Diaz, Kirk N Garratt, Ron Waksman, Laura Edwards, Gudaye Tasissa, Khalid Salahuddin, Hijrah El-Sabae, Carmen Dell'Anna, Linda Davidson-Ray, Jeffrey B Washam, E Magnus Ohman, Tracy Y Wang, Jennifer A Rymer, Deepak L Bhatt, Dominick J Angiolillo, Miguel Diaz, Kirk N Garratt, Ron Waksman, Laura Edwards, Gudaye Tasissa, Khalid Salahuddin, Hijrah El-Sabae, Carmen Dell'Anna, Linda Davidson-Ray, Jeffrey B Washam, E Magnus Ohman, Tracy Y Wang

Abstract

Background In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention-related ischemic complications without increasing major bleeding. This study was performed to examine cangrelor use and transition to oral P2Y12 inhibitors in routine clinical practice. Methods and Results The CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry is a multicenter, retrospective observational study of platelet inhibition strategies for patients with myocardial infarction undergoing percutaneous coronary intervention. In phase 1, data were collected on consecutive patients with myocardial infarction (n=482) treated with any P2Y12 inhibitor to understand cangrelor use by hospital. In phase 2, data were collected in a 2:1 (cangrelor-: non-cangrelor-treated) ratio of patients with myocardial infarction (n=873). In phase 1, cangrelor use varied across hospitals (overall, 50.4% [range, 6.0%-100%]). Of patients receiving cangrelor in both phases (n=819), 3.3% received either the bolus or infusion only. Cangrelor was infused for a median of 121 (76-196) minutes; and 38.3% received an infusion for <2 hours. Most patients transitioned from cangrelor to ticagrelor (ticagrelor, 85.3%; clopidogrel, 9.5%; prasugrel, 5.2%). Many patients (16.4%) had a >1-hour gap between cangrelor cessation and oral P2Y12 inhibitor initiation; this was highest among those transitioned to clopidogrel (56.6% versus 34.5% prasugrel versus 10.8% ticagrelor; P<0.001). Only 27.3% were dosed with cangrelor and transitioned to an oral P2Y12 inhibitor in a fashion consistent with the pivotal trials and US Food and Drug Administration label. Conclusions This multicenter registry demonstrated interhospital variability in how cangrelor was administered and transitioned to an oral P2Y12 inhibitor. These findings highlight opportunities for optimization of cangrelor dosing, infusion duration, and transition of care from the catheterization laboratory to the ward setting.

Keywords: antiplatelet; cangrelor; myocardial infarction.

Figures

Figure 1. Screening and enrollment schema for…
Figure 1. Screening and enrollment schema for phases 1 and 2. MI indicates myocardial infarction.
Figure 2. Variation in use of cangrelor…
Figure 2. Variation in use of cangrelor among consecutive patients with MI in phase 1 across registry sites.
MI indicates myocardial infarction; NSTEMI, non–ST‐segment–elevation myocardial infarction; and STEMI, ST‐segment–elevation myocardial infarction.
Figure 3. Proportion of cangrelor infusion duration…
Figure 3. Proportion of cangrelor infusion duration
Figure 4. Proportion of patients for which…
Figure 4. Proportion of patients for which cangrelor was discontinued before leaving the catheterization laboratory.

References

    1. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35. doi: 10.1177/0091270009344986
    1. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–1313. doi: 10.1056/NEJMoa1300815
    1. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient‐level data. Lancet. 2013;382:1981–1992. doi: 10.1016/S0140-6736(13)61615-3
    1. De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Assoc. 2021;10:e022125. doi: 10.1161/JAHA.121.022125
    1. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318–2329. doi: 10.1056/NEJMoa0908628
    1. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330–2341. doi: 10.1056/NEJMoa0908629
    1. FDA Labeling for Cangrelor. Available at: . Accessed May 10, 2021.
    1. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, et al. International expert consensus on switching platelet P2Y12 receptor‐inhibiting therapies. Circulation. 2017;136:1955–1975.
    1. Desai NR, Kennedy KF, Cohen DJ, Connolly T, Diercks DB, Moscucci M, Ramee S, Spertus J, Wang TY, McNamara RL, et al. Contemporary risk model for in hospital major bleeding for patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry®‐Get With The Guidelines (GWTG)® . Am Heart J. 2017;194:16–24. doi: 10.1016/j.ahj.2017.08.004
    1. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, et al. Baseline risk of major bleeding in non‐ST‐segment‐elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873–1882. doi: 10.1161/CIRCULATIONAHA.108.828541
    1. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Wang TY. Risk adjustment for in‐hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry‐get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011;161:113–122. doi: 10.1016/j.ahj.2010.10.004
    1. Peterson ED, Roe MT, Mulgund J, DeLong ER, Lytle BL, Brindis RG, Smith SC, Pollack CV, Newby LK, Harrington RA, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006;295:1912–1920. doi: 10.1001/jama.295.16.1912
    1. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen‐LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non‐ST‐segment elevation acute coronary syndromes. JAMA. 2005;294:3108–3116. doi: 10.1001/jama.294.24.3108
    1. Gibson CM, Marble SJ. Issues in the assessment of the safety and efficacy of tenecteplase (TNK‐tPA). Clin Cardiol. 2001;24:577–584. doi: 10.1002/clc.4960240903
    1. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7:435–442. doi: 10.1016/j.jcin.2013.08.017
    1. Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26:42–48. doi: 10.1097/MCA.0000000000000158
    1. Vaduganathan M, Qamar A, Badreldin HA, Faxon DP, Bhatt DL. Cangrelor use in cardiogenic shock: a single‐center real‐world experience. JACC Cardiovasc Interv. 2017;10:1712–1714. doi: 10.1016/j.jcin.2017.07.009

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe